About UsNewsShop
Fighting hereditary breast and ovarian cancer
Information & Research
| More


A Study of Oral Rucaparib in Patients With gBRCA Ovarian Cancer, or Other Solid Tumor

Study identifier: NCT01482715
Full study details on clinicaltrials.gov

Name of PARP Inhibitor used in study:

Rucaparib (Clovis)


  • Ovarian cancer associated with a gBRCA mutation that has relapsed >6 months following platinum-based prior treatment and is measurable. Two to four prior treatment regimens permitted.

Type of study:

Phase I/II single-agent. Single group assignment (all participants receive study agent).

Oral tablet administered daily; 21-day cycles of treatment. In Part 1, the initial dose level is 40 mg/day; doses will be escalated in subsequent patient cohorts until Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) are established. Patients enrolled in Part 2 will receive the RP2D daily for continuous 21-day treatment cycles..

Study sites:

Sarah Cannon Research Institute Recruiting
Contact: Heather Rieth at: hrieth@flcancer.com

Dana-Farber Cancer Institute
Contact: Andrew Wolanski at: andrew_wolanski@dfci.harvard.edu

Karmanos Cancer Institute Recruiting
Contact: Entela Rama at: ramae@karmanos.org

Sarah Cannon Research Institute Recruiting
Contact: Julie Pfrommer at: julie.pfrommer@scresearch.net

United Kingdom
University College London Cancer Institute Recruiting
Contact: Rebecca Kristeleit at: r.kristeleit@ucl.ac.uk

Page updated 06/10/13

Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.

Privacy Policy | Sitemap | Contact Us


This site has been made possible by a generous grant from Morphotek.

Web design by Rareheron Web Design

copyright © FORCE: Facing Our Risk of Cancer Empowered, Inc.  •  info@facingourrisk.org